NASDAQ: SGP · Industrial Applications and Services · 4 alerts · CIK 1778922
Share price
$32.24Close, Nov 16
Market cap
$1.08B
Shares outstanding
33.46MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All SpyGlass Pharma, Inc. filings on SEC EDGAR ↗
SpyGlass Pharma reported a net loss of $57.9 million for the nine months ended September 30, 2026, compared to $27.3 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through an initial public offering and the conversion of preferred stock, ending the period with $208.7 million in cash and cash equivalents.
SpyGlass Pharma reported Q3 2026 financial results, highlighting a cash position of $215.8 million which is expected to fund operations through 2028. The company also announced the $13 million acquisition of Advanced Vision Science to secure IOL manufacturing capacity and reported positive four-year follow-up data from its first-in-human study of the BIM-IOL System.
Term
Q3 2026
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability.”
Patrick Mooney, chief executive officer of SpyGlass Pharma
SpyGlass Pharma announced positive 4-year interim results from its first-in-human trial of the BIM-IOL System for glaucoma patients undergoing cataract surgery. The data showed a 37% reduction in mean intraocular pressure and 86% of patients remained off topical drops with no product-related adverse events reported.